TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1098181
Drug: Parenteral administration
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of cephradine
Study: 1098181
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of cephradine
Study: 29941500
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone for 12 months
Study: 31178434
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine for 3 months followed by metformin for 9 months
Study: 31178434
Drug: Liraglutide combined
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide combined with metformin for 12 months
Study: 25291499
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg daily for 8 weeks)
Study: 18465191
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) after subgingival scaling and root planing
Study: 14971587
Drug: Levodopa (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (2 mg/kg body weight)
Study: 8751022
Drug: 4% erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% erythromycin plus 1.2% zinc (Zineryt lotion)
Study: 8751022
Drug: 4% erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% erythromycin lotion (control)
Study: 90768
Drug: Concurrent induced-abortion/sterilisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent induced-abortion/sterilisation group
Study: 26564297
Drug: Sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2 mg/kg intravenously)
Study: 26564297
Drug: Neostigmine/atropine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine/atropine combination (0.05 mg/kg neostigmine and 0.02 mg/kg atropine)
Study: 16600415
Drug: Sequential changes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential changes in fasting plasma glucose (FPG) levels within the normoglycemic range (FPG<100 mg/dl)
Study: 8132365
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once daily for 10 days
Study: 8132365
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 1 million U three times daily for 10 days
Study: 19336502
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to aspirin
Study: 27596801
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (n=10) received Lactobacillus rhamnosus SP1 at a dose of 3×10^9 cfu/day (75 mg/day)
Study: 22385118
Drug: Gonadotropin treatment
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin treatment (GnTh) using β Human Chorionic Gonadotropin (β HCG) and Follicle Stimulating Hormone (FSH) for up to 30 months.
Study: 12475576
Drug: Dinoprostone 0.5
Normalized name: dinoprostone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone 0.5 mg doses given intra-cervically every 6 h
Study: 10391423
Drug: Monitoring with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring with antifactor Xa heparin activity (HA)
Study: 8655902
Drug: Fortified formula
Normalized name: B-Complex Fortified Formula Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified formula (alpha-linolenic acid 1.8 g/day, arginine 7.8 g/day, RNA 0.75 g/day)
Study: 12462952
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement 'ExPress'
Study: 2684078
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (750 mg every 12 hours)
Study: 2684078
Drug: Intravenous cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefotaxime (2.0 g every 8 hours)
Study: 240378
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg oral dose)
Study: 23869185
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at infusion rate of 0.1 μg·kg(‐1)·min(‐1) (Group L)
Study: 23869185
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at infusion rate of 0.5 μg·kg(‐1)·min(‐1) (Group H)
Study: 21047149
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment for opioid dependence
Study: 15022297
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy with carboplatin chemotherapy
Study: 15022297
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy with carboplatin chemotherapy
Study: 15022297
Drug: Radiotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy without carboplatin chemotherapy
Study: 11750220
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GR‐1/Lactobacillus fermentum RC‐14 (once and twice daily)
Study: 8000301
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of beta-carotene (BC) daily for 3 months
Study: 2725335
Drug: Nomegestrol acetate
Normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Nomegestrol acetate 0.5 mg daily
Study: 2725335
Drug: Nomegestrol acetate
Normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Nomegestrol acetate 1.0 mg daily
Study: 2725335
Drug: Nomegestrol acetate
Normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Nomegestrol acetate 2.5 mg daily
Study: 2725335
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oestrogen therapy only)
Study: 781439
Drug: 410 mg
Normalized name: aspirin 410 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 410 mg of prednisone plus vitamins in descending doses over 10 days
Study: 20105150
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target controlled infusion
Study: 17481578
Drug: High chronic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High chronic stress group (post hoc division based on chronic daily stress questionnaire)
Study: 17481578
Drug: Low chronic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low chronic stress group (post hoc division based on chronic daily stress questionnaire)
Study: 2342818
Drug: Oral immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunization with inactivated influenza vaccine (Mississippi 1/85; dosage: 110 micrograms HA)
Study: 31498862
Drug: Papaverine injection
Normalized name: papaverine Injection
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine injection (0.1 or 0.2 cc)
Study: 31498862
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine AVF construction without papaverine injection)
Study: 19171333
Drug: prolonged GnRHa
Approvals — FDA: no, EMA: no, PMDA: no
Description: prolonged GnRHa (depot leuprolide acetate 3.75 mg every 28 days for three doses)
Study: 16716615
Drug: memantine (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine (20-30 mg daily, n=10)
Study: 2385207
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous infusion of 10 mg of Propionibacterium avidum KP-40
Study: 2385207
Drug: Postoperative re-infusion
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative re-infusion of Propionibacterium avidum KP-40
Study: 6156361
Drug: Minoxidil in
Normalized name: Product containing minoxidil in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil in combination with propranolol at a dosage ratio of 1:8
Study: 6156361
Drug: Minoxidil in
Normalized name: Product containing minoxidil in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil in combination with propranolol at dosage ratios of 1:2 and 1:4
Study: 25882910
Drug: Low-dose LPS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose LPS (0.4 ng/kg body weight)
Study: 21535913
Drug: Grass MATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass MATA MPL (300-2000 standardized units/injection)
Study: 14727971
Drug: Percutaneous myocardial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous myocardial revascularization (PMR) plus medical therapy
Study: 8553675
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II induced hypertension chemotherapy (IHC)
Study: 105101
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg daily for 3 days at the onset of symptoms)
Study: 12715685
Drug: Nicergoline (Adavin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (Adavin 60 mg/d)
Study: 30541065
Drug: Losartan 50-100
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50-100 mg/d
Study: 30541065
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil 1,400-2,800 mg/d
Study: 29624542
Drug: Single-shot epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot epidural block with 0.25% bupivacaine plus 4 mg of morphine (10 mL) combined with general anesthesia.
Study: 29624542
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (B and G)
Study: 20493481
Drug: Anesthesiologist-administered sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesiologist-administered sedation (AAS) using propofol-remifentanil (PR)
Study: 17609490
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (6.3 g per day containing 30 mg of polyphenols)
Study: 689746
Drug: Antibiotic decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic decontamination with neomycin, polymyxin, bacitracin, and nystatin (Group A)
Study: 31469017
Drug: Ultrasonic debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic debridement plus recombinant human fibroblast growth factor (FGF) gel
Study: 29496253
Drug: Induction radiochemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction radiochemotherapy followed by consolidation chemotherapy (arm A)
Study: 29496253
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by consolidation concurrent radiochemotherapy (arm B)
Study: 26902765
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.5 g meropenem
Study: 26902765
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of 0.5 g meropenem
Study: 20338954
Drug: Spinal analgesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal analgesia (bupivacaine 7.5 mg)
Study: 17328965
Drug: IFN‐beta‐1a 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐beta‐1a 30 microg intramuscularly (IM) once‐weekly (qw) (n=8)
Study: 17328965
Drug: IFN‐beta‐1a 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐beta‐1a 44 microg subcutaneously (SC) three‐times‐weekly (tiw) (n=7)
Study: 16353395
Drug: i.v. dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. dexamethasone (10 mg in 2 ml)
Study: 16353395
Drug: i.v. placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. placebo (2 ml of normal saline)
Study: 11432685
Drug: m-CPP (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CPP (0.4 mg/kg)
Study: 9752300
Drug: Morphine (M)
Normalized name: morphine Extended Release Oral Capsule [M-Eslon]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (M) therapy
Study: 9752300
Drug: No Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Morphine (M-)
Study: 8783312
Drug: Naloxone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (6 mg i.v.)
Study: 31291976
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at 'Wang's Jiaji' acupoints, five times a week for 2 weeks.
Study: 19690559
Drug: Metformin continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin continued after switching to insulin
Study: 11093927
Drug: DIU (diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIU (diuretic administration; Novotriamazide; 100 mg triamterene and 50 mg hydrochlorothiazide)
Study: 9028776
Drug: Sequential Japanese
Normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Japanese sentences (speech)
Study: 8174724
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) 2 mg SC
Study: 3371847
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon (a‐IFN) treatment at a standard i.m. dose of 0.7‐1.0 X 10(5)/kg/day for 28 consecutive days, followed by the same dose twice a week for two months.
Study: 27550552
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered by nonclinician sleep coaches
Study: 19347247
Drug: 42 g
Normalized name: PETROLATUM 42 g in 100 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 g of protein supplement (SUP) ingested pre- and post-exercise
Study: 7622080
Drug: Citicoline (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (1000 mg i.m. daily for 15 days)
Study: 1978467
Drug: Remoxipride (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (mean daily dose 353 mg)
Study: 1978467
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean daily dose 11 mg)
Study: 609193
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (200 mg i.m. weekly)
Study: 16354469
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ofloxacin plus 600 mg of rifampicin (OR, n = 41)
Study: 16354469
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of doxycycline plus 600 mg of rifampicin (DR, n = 45)
Study: 16354469
Drug: 1g intramuscularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g intramuscularly streptomycin plus 200 mg doxycycline (DS, n = 32)
Study: 11245347
Drug: Combination vaccine
Normalized name: Hepatitis vaccine combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vaccine
Study: 9855438
Drug: Separately administered
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separately administered components
Study: 7715294
Drug: Saquinavir 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir 25 mg three times daily
Study: 7715294
Drug: Saquinavir 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir 75 mg three times daily
Study: 7715294
Drug: Saquinavir 200
Normalized name: saquinavir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir 200 mg three times daily
Study: 7715294
Drug: Saquinavir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir 600 mg three times daily
Study: 1013853
Drug: Povidone-iodine douche
Normalized name: povidone-iodine Douche
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine douche and gel
Study: 1013853
Drug: Other methods
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other methods of vaginal preparation
Study: 29493163
Drug: ACPV decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACPV decoction (treatment group)
Study: 25409167
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac (90 mg)
Study: 23328126
Drug: Omega-3-Acid Ethyl
Normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3-Acid Ethyl Esters (4 g/day)
Study: 12799091
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg/d
Study: 15655130
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/d
Study: 17086021
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/d + Quinapril 20 mg/d
Study: 15577824
Drug: Total serum
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total serum IgE level greater than 100 IU/mL
Study: 12033350
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic drug therapy or ICD
Study: 2427858
Drug: Celiprolol treatment
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol treatment
Study: 31002317
Drug: Minimally interrupted
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally interrupted dabigatran therapy
Study: 31002317
Drug: Uninterrupted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted warfarin therapy
Study: 24048776
Drug: Symphytum herb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symphytum herb extract cream
Study: 22691828
Drug: Tachosil® (hemostatic-sealant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tachosil® (hemostatic-sealant drug) used as a reinforcement of the suture line in sleeve gastrectomy
Study: 7954550
Drug: Xipamide, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xipamide, 20 mg/day
Study: 7954550
Drug: Spironolactone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, 200 mg/day combined with furosemide, 40 mg on alternate days
Study: 7954550
Drug: Torasemide, 10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide, 10-40 mg/day combined with spironolactone, 50-400 mg/day
Study: 3661610
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g suspension four times daily for eight weeks
Study: 3661610
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg four times daily for eight weeks
Study: 29660190
Drug: HBAI20 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBAI20 vaccine
Study: 12570120
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone (200 microg twice daily)
Study: 1382539
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg orally, 4 h before injection)
Study: 3988974
Drug: Amitriptyline 150
Normalized name: amitriptyline 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 150 mg/day for 6 weeks
Study: 29746294
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily Atripla regimen (OD)
Study: 23924587
Drug: Adefovir (ADV)
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir (ADV) therapy
Study: 18195173
Drug: Clopidogrel 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 0.20 mg/kg/day
Study: 11092064
Drug: Nicotine 2‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 2‐mg sublingual tablet
Study: 1534211
Drug: Teicoplanin 3
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 3 mg/kg
Study: 2149493
Drug: Teicoplanin 12
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 12 mg/kg
Study: 1534211
Drug: Teicoplanin 30
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 30 mg/kg
Study: 1534211
Drug: Combined results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined results of all doses (3, 12, 30 mg/kg)
Study: 6330886
Drug: 28-day famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28-day famotidine treatment
Study: 29800211
Drug: Fremanezumab monthly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab monthly dosing (225 mg at baseline, week 4, and week 8)
Study: 29800211
Drug: Fremanezumab single
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab single higher dose (675 mg at baseline; placebo at weeks 4 and 8)
Study: 26294680
Drug: Pilates-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates-based program twice a week for 6 weeks
Study: 24478399
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during clamp
Study: 24478399
Drug: Intralipid/heparin mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid/heparin mixture